New and Emerging ALK/ROS1/NTRK-Targeted Agents in NSCLC: Addressing Treatment Resistance and CNS Metastases
CE Information1.0 CME credit
Completion Time60 minutes
Available UntilJanuary 20, 2024
Posted ByHMP Global
SpecialtiesHematology / Oncology
Clinical TopicsLung Cancer
This on-demand webcast is available with synchronized slides and video/audio.
To be eligible for credit, participants must complete the educational activity, complete the 4-question post-test with a minimum score of 70%, and complete the activity evaluation form. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.
Release Date: January 20, 2023.
Expiration Date: January 20, 2024.
Estimated Time to Complete: 1.00 hour
There is no fee associated with this activity.
After participating in this activity, learners should be better able to:
- Assess guideline recommendations, testing techniques, and clinical applications for molecular profiling to identify patients who will benefit from ALK, ROS1, or NTRK-targeted therapy
- Evaluate clinical efficacy and safety data for new and emerging ALK, ROS1, and NTRK-targeted agents against treatment resistance and CNS metastases
- Utilize adverse event management strategies to optimize treatment efficacy and mitigate treatment risks
This activity offers 1.0 CME credit to attendees.
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.Log in and start activity